Boehringer Ingelheim Corporation, Wellpoint, And HealthCore Announce First Project Under Multi-Year Research Collaboration

RIDGEFIELD, Conn. & WILMINGTON, Del.--(BUSINESS WIRE)--Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), WellPoint and HealthCore, announced today that the companies are commencing a research project to identify and address unmet medical needs across populations of mutual interest.

The first stage of the project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, and the use of evidence-based guidelines. This project is the first under the parties’ five-year research collaboration agreement, signed earlier this year.

Information gathered through the NVAF project is intended to provide the basis for the collaborative development of healthcare interventions, which can be evaluated within WellPoint’s affiliated health plans and provider networks.

Help employers find you! Check out all the jobs and post your resume.

Back to news